TAGRISSO 80 mg film-coated tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc)
Tagrisso, INN-osimertinib
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Landmark overall survival at 2 years and 2.5 years in patients treated... | Download Scientific Diagram
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status - ScienceDirect
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Efficacy of Metastatic NSCLC – TAGRISSO® (osimertinib) Nurse Center
Asco 2020 – Tagrisso shows what early targeting can do | Evaluate
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Efficacy of Metastatic NSCLC – TAGRISSO® (osimertinib) Nurse Center
Efficacy of Resectable NSCLC – TAGRISSO® (osimertinib) Nurse Center
AZ's lung cancer drug extends survival period in P3 study < Pharma < Article - KBR
Tagrisso Approved as Adjuvant Therapy for Early-Stage EGFR-Mutant NSCLC - MPR
Osimertinib in Advanced Lung Cancer with EGFR Mutations - NCI
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis | BMC Cancer | Full Text
Overall survival in patients with or without chemotherapy after... | Download Scientific Diagram
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
AURA3 Clinical Study Data – TAGRISSO® (osimertinib)
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
